PRF Technologies (NASDAQ:PRFX) shares tumbled on Tuesday. Last week, the company released a year-end business update that lays out its healthcare and AI-driven solar priorities. The selling picks up as investors digest progress updates and the Nasdaq is trading lower.
2025 Key Events
PRF’s highlighted a majority investment in Boston-based LayerBio in August 2025, adding the OcuRing-K program and expanding its ocular drug-delivery focus beyond post-operative pain.
PRF Technologies completed the acquisition of DeepSolar, entering the AI-driven solar analytics market and establishing a second high-growth business platform.
The company ended 2025 with around $4.1 million in cash, cash equivalents, short-term deposits, and restricted cash, and positive working capital of about $2.0 million.
Dr. Ehud Geller, Executive Chairman of PRF Technologies, added, “2025 was a transformational year for PRF as we repositioned the Company into a diversified innovation platform spanning healthcare and renewable-energy analytics. In healthcare, we significantly strengthened our pipeline and strategic focus through our majority investment in LayerBio and the continued advancement of OcuRing-K, which we believe has the potential to address a large unmet need in cataract surgery through a truly drop-less, sustained-release approach.”